Skip to content
Iodixanol
Visipaque (iodixanol) is an unknown pharmaceutical. Iodixanol was first approved as Visipaque 270 on 1996-03-22.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Visipaque (generic drugs available since 2022-05-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iodixanol
Tradename
Company
Number
Date
Products
VISIPAQUE 270GE HealthcareN-020351 RX1996-03-22
1 products, RLD, RS
VISIPAQUE 320GE HealthcareN-020351 RX1996-03-22
1 products, RLD, RS
VISIPAQUE 320GE HealthcareN-020808 RX1997-08-29
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
visipaqueNew Drug Application2023-05-08
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
IODIXANOL, IODIXANOL, HENGRUI PHARMA
2023-01-09CGT
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
V08: Contrast media
V08A: X-ray contrast media, iodinated
V08AB: Watersoluble, nephrotropic, low osmolar x-ray contrast media
V08AB09: Iodixanol
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic granulomatous diseaseD006105EFO_0000338D711214
Wiskott-aldrich syndromeD014923D82.011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Friedreich ataxiaD005621Orphanet_95G11.11336
Pulmonary fibrosisD011658J84.101135
MelanomaD0085452114
Lung diseasesD008171EFO_0003818J98.4134
OsteopetrosisD010022Q78.22114
Idiopathic pulmonary fibrosisD054990J84.112134
Ovarian neoplasmsD010051EFO_0003893C561113
Breast neoplasmsD001943EFO_0003869C501213
CandidemiaD058387EFO_1001282112
PneumoniaD011014EFO_0003106J18112
Show 9 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B203316
HivD006678O98.72224
NeoplasmsD009369C80224
Pulmonary tuberculosisD014397EFO_1000049A151224
Chronic hepatitis cD019698EFO_0004220B18.233
TuberculosisD014376EFO_0000774A15-A19123
Mycobacterium avium-intracellulare infectionD015270EFO_0007386112
Colorectal neoplasmsD01517922
Fallopian tube neoplasmsD005185112
Synovial sarcomaD013584112
Show 41 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D4622
NeuroblastomaD009447EFO_000062111
OsteosarcomaD01251611
Ewing sarcomaD012512EFO_000017311
RhabdomyosarcomaD01220811
Myeloid leukemiaD007951C9211
XerostomiaD014987K11.711
GlioblastomaD005909EFO_000051511
PsoriasisD011565EFO_0000676L4011
Ovarian epithelial carcinomaD00007721611
Show 1 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Latent tuberculosisD055985Z22.733
Respiratory tract infectionsD012141J06.933
Covid-19D000086382U07.111
SarcoidosisD012507EFO_0000690D80-D8911
Viral pneumoniaD011024EFO_0007541J12.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIODIXANOL
INNiodixanol
Description
Iodixanol is a dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography. It has a role as a radioopaque medium.
Classification
Small molecule
Drug classiodine-containing contrast media
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
Identifiers
PDB
CAS-ID92339-11-2
RxCUI27729
ChEMBL IDCHEMBL1200507
ChEBI ID31705
PubChem CID3724
DrugBankDB01249
UNII IDHW8W27HTXX (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,871 documents
View more details
Safety
Black-box Warning
Black-box warning for: Visipaque
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,392 adverse events reported
View more details